USA: Risk Stratification Can Predict Outcomes for CAR T-Cell Therapy in Lymphoma

For patients with diffuse large B-cell lymphoma (DLBCL), a simple risk stratification can predict outcomes for patients treated with CD19 chimeric antigen receptor (CAR) T-cell therapy, according to a study published online Feb. 8 in Blood Cancer Discovery.

Noting that some patients with DLBCL treated with CD19 CAR T-cell therapy have poor clinical outcomes, Rawan G. Faramand, M.D., from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues examined serum proteins associated with severe immune-mediated toxicities and inferior clinical responses in 146 patients with relapsed or refractory DLBCL who were treated with axicabtagene ciloleucel. Patients were classified into low-, intermediate-, and high-risk groups using a simple stratification developed based on prelymphodepletion C-reactive protein and ferritin.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=NzE4NmQ4YTgtYWU4My00ZjJiLThhYWEtMjhiNTg3OTU2MzA2&client=Nw%3D%3D&section=undefined